Merck to Begin Late-Stage Trial of HIV Prevention Drug, With Help from Bill & Melinda Gates Foundation
November 16 2020 - 7:27AM
Dow Jones News
By Dave Sebastian
Merck & Co. Inc. said it expects to move ahead with its
Phase 3 trial to assess islatravir as an HIV treatment and
prevention by early 2021.
The study will look into the once-monthly pre-exposure
prophylaxis treatment option in women and adolescent girls at risk
of contracting the virus that causes AIDS in sub-Saharan Africa,
the pharmaceutical company said Monday.
The company said it is working with the Bill & Melinda Gates
Foundation on the study. The foundation will provide grants to the
International Clinical Research Center at the University of
Washington Department of Global Health, which is collaborating with
Merck on the study, the company said. Merck didn't disclose the
amount of the foundation's contribution.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
November 16, 2020 07:12 ET (12:12 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024
